N-Of-One To Provide Clinical Interpretation To The Diagnostic Laboratories Awarded The US Department Of Veteran Affairs Contract For Clinical Cancer Genomic Testing In New England

N-of-One to enrich molecular profiling results with clinical and scientific evidence and targeted therapy options, initially focused on lung cancer patients, for the Veterans Integrated Service Network 1 (VISN 1) Precision Oncology Program

LEXINGTON, Mass.--(BUSINESS WIRE)--N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced that the company will provide the clinical interpretation for all genomic tests to be conducted for the New England Veterans Integrated Service Network (VISN 1) Precision Oncology Program. N-of-One will work closely with Personalis and Personal Genome Diagnostics (PGDx), the two leading diagnostic laboratories that have been awarded contracts by the Department of Veterans Affairs to perform this genomic testing.

“The N-of-One team of scientists, oncologists, and technologists looks forward to working closely with Personalis and PGDx laboratories to support the success of the New England Veterans Integrated Service Network 1 (VISN 1) Precision Oncology Program”

N-of-One Clinical Interpretation is based on proven, deep oncology domain expertise that is constantly updated by the in-house team of PhDs and oncologists. N-of-One delivers scientific and clinical evidence that supports possible therapeutic strategies relevant to each specific patient case, and is configured to easily and efficiently integrate into each organization's reporting needs.

The Personalis ACE Extended Cancer Panel for DNA and RNA Analysis will provide comprehensive and detailed genomic profiling of solid tumors and identification of potential targeted treatment options for VA New England Healthcare System patients. Personalis will process this sequencing data using its proprietary cancer informatics pipeline. By combining DNA and RNA analysis, and covering over 1,500 genes, Personalis’ testing provides comprehensive data for both clinical testing and ongoing research use at the VA.

PGDx’s CancerSelect™ targeted gene panel, which will be run for patients in the program with newly-diagnosed lung cancer, detects alterations in 88 well-characterized genes that include nearly all targets of currently available or investigational cancer treatments. CancerSelect uses next-generation sequencing technology to identify somatic mutations, focal amplifications, and translocations in the genes that have the greatest potential to impact treatment decisions.

“The N-of-One team of scientists, oncologists, and technologists looks forward to working closely with Personalis and PGDx laboratories to support the success of the New England Veterans Integrated Service Network 1 (VISN 1) Precision Oncology Program,” said Chris Cournoyer, N-of-One CEO.

About N-of-One
N-of-One, a leader in enabling precision medicine for oncology, leverages its world-class team of PhD and oncologist experts coupled with a highly proprietary platform that allows us to provide clinical solutions and services, such as molecular interpretation, to clinicians at the point of care. N-of-One’s team of experts has interpreted thousands of samples for oncologists and patients worldwide, through partnerships with leading diagnostic companies and hospital systems, as well as directly to oncologists and through employee access benefit programs. N-of-One does not provide medical advice or promote any product or service. For more information, please visit www.n-of-one.com or call 617-202-9808.